Skip to main
  1. Stocks
  2. Spyre Therapeutics Inc
  3. Forecast
SYRE

SYRE Stock Forecast & Price Target

SYRE Analyst Ratings

Based on 15 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spyre Therapeutics is attractive because its core IBD thesis is supported by strong monotherapy validation across SPY001, SPY002, and SPY003, with SPY001 showing 40% clinical remission at week 12 and the platform trial’s Part B moving ahead of expectations. The 3Q26 SPY072 setback in PsA and axSpA weakens rheumatology upside, but it does not materially impair the company’s main value drivers because TL1A still has stronger validation in IBD and the program is being repositioned into HS, where a pivotal study is planned for 2027. Financially, the company ended 3Q26 with $1.07B in cash and investments, later raised about $396MM net for pro forma cash of roughly $1.47B, supporting an expected runway into 2H29 while key catalyst readouts remain scheduled for 3Q27 and late 2027/early 2028.

Bears say

Spyre Therapeutics is a clinical-stage biotech facing substantial regulatory uncertainty, because accelerated approval paths may still require additional data, longer studies, or revised requirements that could delay or even prevent commercialization. Its prospects are also weakened by competitive pressure, since rival updates can materially affect sentiment and the company may fail to secure product labels with the features needed to gain traction in inflammatory bowel disease and other immune-mediated diseases. Financially, the business is dependent on capital markets to fund development and future commercialization, and an inability to raise adequate capital would threaten continued pipeline advancement despite its single-segment focus on biopharmaceutical development.

SYRE has been analyzed by 15 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spyre Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

SYRE Analyst Forecast & Price Prediction

Get the latest SYRE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SYRE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spyre Therapeutics Inc (SYRE) Forecast

Analysts have given SYRE a Strong Buy based on their latest research and market trends.

According to 15 analysts, SYRE has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $108.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $108.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spyre Therapeutics Inc (SYRE)


SYRE Analyst Forecast & Price Prediction

Get the latest SYRE stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SYRE

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SYRE stock data and trends